Search

Fred Ledley Phones & Addresses

  • Laurel, MD

Publications

Us Patents

Methods Of Treating Autoimmune Diseases And Transplantation Rejection

View page
US Patent:
58719504, Feb 16, 1999
Filed:
Jun 5, 1995
Appl. No.:
8/460886
Inventors:
Dinah S. Singer - Chevy Chase MD
Leonard Kohn - Bethesda MD
Edna Mozes - Rehovot, IL
Motoyasu Saji - Rockville MD
Jocelyn Weissman - Silver Spring MD
Giorgio Napolitano - Rockville MD
Fred D. Ledley - Houston TX
International Classification:
C12Q 102
C12Q 100
G01N 3353
A01N 6100
US Classification:
435 29
Abstract:
The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.

Methods For Assessing The Ability Of A Candidate Drug To Suppress Mhc Class I Expression

View page
US Patent:
55567541, Sep 17, 1996
Filed:
Jun 7, 1995
Appl. No.:
8/480525
Inventors:
Dinah S. Singer - Chevy Chase MD
Leonard Kohn - Bethesda MD
Edna Mozes - Rehovot IL
Motoyasu Saji - Rockville MD
Jocelyn Weissman - Silver Spring MD
Giorgio Napolitano - Rockville MD
Fred D. Ledley - Houston TX
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12Q 168
C12P 1934
C07H 2104
US Classification:
435 6
Abstract:
The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. The methods of treatment involve the use of drugs capable of suppressing expression of MHC Class I molecules. In particular the use of the drug methimazole to suppress expression of MHC Class I molecules in the treatment of autoimmune diseases and the prevention or treatment of rejection in a transplant recipient is disclosed. In addition in vivo and in vitro assays are provided for the assessment and development of drugs capable of suppressing MHC Class I molecules.
Fred D Ledley from Laurel, MD Get Report